Go6976 is a novel and potent inhibitor of JAK2 and JAK3 tyrosine kinases both in vitro and in cellular assays

被引：0

作者：

Grandage, VL ^{[1
]}

Linch, DC ^{[1
]}

Khwaja, A ^{[1
]}

机构：

[1] UCL Royal Free & UCL Med Sch, Dept Haematol, London, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2005年 / 129卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6 / 6

页数：1

共 50 条

[41] SB1518, a novel JAK2/FLT3 inhibitor for the treatment of myeloid malignancies
Hart, Stefan
Goh, Kee Chuan
Novotny-Diermayr, Veronica Veronica
Tan, Yong Cheng
Madan, Babita
Amalini, Chithra
Loh, Yung Kiang
Ong, Lai Chun
Williams, Anthony
Lee, Angeline
Poulsen, Anders
Jayaraman, Ramesh
Ethirajulu, Kantharaj
Dymock, Brian W.
Wood, Jeanette M.
CANCER RESEARCH, 2011, 71
[42] The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway
Madden, Timothy
Kazerooni, Reza
Myer, Jeffrey
Culotta, Kirk
Donato, Nicholas
Johansen, Mary J.
Kondo, Yasuko
Mack, David
Priebe, Waldemar
CANCER RESEARCH, 2006, 66 (08)
[43] Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor
Yin-jun Lou
Acta Pharmacologica Sinica, 2012, 33 : 212 - 213
[44] Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma
Nairismagi, M. -L.
Gerritsen, M. E.
Li, Z. M.
Wijaya, G. C.
Chia, B. K. H.
Laurensia, Y.
Lim, J. Q.
Yeoh, K. W.
Yao, X. S.
Pang, W. L.
Bisconte, A.
Hill, R. J.
Bradshaw, J. M.
Huang, D.
Song, T. L. L.
Ng, C. C. Y.
Rajasegaran, V.
Tang, T.
Tang, Q. Q.
Xia, X. J.
Kang, T. B.
Teh, B. T.
Lim, S. T.
Ong, C. K.
Tan, J.
LEUKEMIA, 2018, 32 (05) : 1147 - 1156
[45] Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma
M. -L. Nairismägi
M. E. Gerritsen
Z. M. Li
G. C. Wijaya
B. K. H. Chia
Y. Laurensia
J. Q. Lim
K. W. Yeoh
X. S. Yao
W. L. Pang
A. Bisconte
R. J. Hill
J. M. Bradshaw
D. Huang
T. L. L. Song
C. C. Y. Ng
V. Rajasegaran
T. Tang
Q. Q. Tang
X. J. Xia
T. B. Kang
B. T. Teh
S. T. Lim
C. K. Ong
J. Tan
Leukemia, 2018, 32 : 1147 - 1156
[46] Design and synthesis of novel pyrrolo[2,3-d]pyrimidine derivatives as potent JAK3 and SYK dual inhibitors
Wang, Liwei
Zhang, Xuecong
Huang, Yinqiao
Xu, Zihan
Ni, Dongxuan
Li, Xiaoli
Ke, Yafang
Xiao, Weilie
Zhang, Ruihan
JOURNAL OF MOLECULAR STRUCTURE, 2024, 1318
[47] Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms
Hu, Mengshi
Yang, Tao
Yang, Linyu
Niu, Lu
Zhu, Jinbing
Zhao, Ailin
Shi, Mingsong
Yuan, Xue
Tang, Minghai
Yang, Jianhong
Pei, Heying
Yang, Zhuang
Chen, Qiang
Ye, Haoyu
Niu, Ting
Chen, Lijuan
BLOOD CANCER JOURNAL, 2022, 12 (03)
[48] Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia
Gunawan, Arief S.
McLornan, Donal P.
Wilkins, Bridget
Waghorn, Katherine
Hoade, Yvette
Cross, Nicholas C. P.
Harrison, Claire N.
HAEMATOLOGICA, 2017, 102 (06) : E238 - E240
[49] Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of Jak2 tyrosine kinase autophophorylation
Sandberg, EM
Ma, XY
He, K
Frank, SJ
Ostrov, DA
Sayeski, PP
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) : 2526 - 2533
[50] CS12192: A novel selective and potent JAK3 inhibitor mitigates acute graft-versus-host disease in bone marrow transplantation
Huang, Shengjian
Yang, Qianjiao
Zhou, You
Li, Lingjie
Shan, Song
TRANSPLANT IMMUNOLOGY, 2024, 85

← 1 2 3 4 5 →